Yeon S. Seo

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 219 publications

A Novel Anchoring Catheter Improves the Success, Efficiency, and Satisfaction of Paracentesis in Refractory Ascites: A Multicenter Randomized Crossover Trial.

A Novel Anchoring Catheter Improves the Success, Efficiency, and Satisfaction of Paracentesis in Refractory Ascites: A Multicenter Randomized Crossover Trial.

Journal: Journal of gastroenterology and hepatology

Published: August 15, 2026

Observational, Post-marketing Surveillance of Safety and Effectiveness of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C.

Observational, Post-marketing Surveillance of Safety and Effectiveness of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C.

Journal: Infectious diseases and therapy

Published: December 11, 2025

Association Between SGLT2 Inhibitor Use and Reduced Risk of Liver-Related Events, Including Hepatocellular Carcinoma, in Diabetic Patients with Viral Hepatitis: A Nationwide Cohort Study.

Association Between SGLT2 Inhibitor Use and Reduced Risk of Liver-Related Events, Including Hepatocellular Carcinoma, in Diabetic Patients with Viral Hepatitis: A Nationwide Cohort Study.

Journal: Cancers

Published: November 03, 2025

Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of HCC Development in Patients With CHB.

Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of HCC Development in Patients With CHB.

Journal: Journal of gastroenterology and hepatology

Published: October 14, 2025

Efficacy and Safety of Switching from Entecavir to Tenofovir Alafenamide in Chronic Hepatitis B: A Multicenter Randomized Trial in Korea.

Efficacy and Safety of Switching from Entecavir to Tenofovir Alafenamide in Chronic Hepatitis B: A Multicenter Randomized Trial in Korea.

Journal: Gut and liver

Published: September 29, 2025

Besifovir dipivoxil maleate versus other antivirals in reducing hepatocellular carcinoma in chronic hepatitis B.

Besifovir dipivoxil maleate versus other antivirals in reducing hepatocellular carcinoma in chronic hepatitis B.

Journal: Scientific reports

Published: May 03, 2025

Identifying sorafenib benefit among patients with hepatocellular carcinoma: A transcriptomic and genomic approach.

Identifying sorafenib benefit among patients with hepatocellular carcinoma: A transcriptomic and genomic approach.

Journal: JHEP reports : innovation in hepatology

Published: March 21, 2025

Enhanced Prediction of Hepatitis B Virus-Related Hepatocellular Carcinoma Using Age-Male-Albumin-Bilirubin-Platelet (aMAP) and Liver Stiffness Assessed by Vibration-Controlled Transient Elastography.

Enhanced Prediction of Hepatitis B Virus-Related Hepatocellular Carcinoma Using Age-Male-Albumin-Bilirubin-Platelet (aMAP) and Liver Stiffness Assessed by Vibration-Controlled Transient Elastography.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: February 03, 2025

Aetiology of chronic liver disease is a valuable factor for stratifying adverse outcomes of acute decompensation: prospective observational study.

Aetiology of chronic liver disease is a valuable factor for stratifying adverse outcomes of acute decompensation: prospective observational study.

Journal: Annals of medicine

Published: January 24, 2025

Need of Treatment Modification During Entecavir Therapy in Patients with Chronic Hepatitis B: Long-Term Follow-Up Results for 120 Months.

Need of Treatment Modification During Entecavir Therapy in Patients with Chronic Hepatitis B: Long-Term Follow-Up Results for 120 Months.

Journal: Microorganisms

Published: December 22, 2024

Risk of Hepatocellular Carcinoma Decreases After Antiviral Therapy-Induced HBsAg Seroclearance.

Risk of Hepatocellular Carcinoma Decreases After Antiviral Therapy-Induced HBsAg Seroclearance.

Journal: Journal of gastroenterology and hepatology

Published: November 13, 2024

Real-world safety and effectiveness of lenvatinib in unresectable hepatocellular carcinoma in Korea: post-marketing study.

Real-world safety and effectiveness of lenvatinib in unresectable hepatocellular carcinoma in Korea: post-marketing study.

Journal: Future oncology (London, England)

Published: September 25, 2024

Showing 1-12 of 219

Last Updated: 09/26/2026